Literature DB >> 6193913

Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura.

T Tsubakio, Y Kurata, S Katagiri, Y Kanakura, T Tamaki, J Kuyama, Y Kanayama, T Yonezawa, S Tarui.   

Abstract

T cell subsets of peripheral lymphocytes were studied using monoclonal antibodies (OKT3, OKT4, OKT8) and immunoglobulin (IgG, IgM, IgA) synthesis in vitro by peripheral mononuclear cells stimulated with pokeweed mitogen was studied in adult patients with idiopathic thrombocytopenic purpura before and after high-dose intravenous intact gamma(gamma-)globulin therapy, at a daily dose of 0.4g/kg body weight for 5 consecutive days. A transient increase in platelet count which reached a peak on the 1st to 2nd days after the end of the therapy was observed in four of five patients. Immunoglobulin synthesis in vitro was suppressed remarkably following therapy in all cases: the mean reduction of IgG, IgM and IgA was 78, 66 and 48%, respectively. Titres of various autoantibodies, TGHA, MCHA, ANF and anti-DNA antibody, also decreased following therapy. In correspondence to this, phenotypic analysis in T cell subsets showed a decrease of OKT4+:OKT8+ ratio following therapy, without a change in the proportion of OKT3+ cells. These data indicate that the intravenous gamma-globulin preparations suppressed synthesis of antibodies non-specifically and caused a relative increase of OKT8+ suppressor T cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193913      PMCID: PMC1535632     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine.

Authors:  P R KIND; E J KING
Journal:  J Clin Pathol       Date:  1954-11       Impact factor: 3.411

2.  Monoclonal antibodies defining distinctive human T cell surface antigens.

Authors:  P Kung; G Goldstein; E L Reinherz; S F Schlossman
Journal:  Science       Date:  1979-10-19       Impact factor: 47.728

3.  Functional analysis of human T cell subsets defined by monoclonal antibodies. I. Collaborative T-T interactions in the immunoregulation of B cell differentiation.

Authors:  Y Thomas; J Sosman; O Irigoyen; S M Friedman; P C Kung; G Goldstein; L Chess
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

4.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

5.  Quantification of platelet-associated IgG with competitive solid-phase enzyme immunoassay.

Authors:  T Tsubakio; Y Kurata; T Yonezawa; T Kitani
Journal:  Acta Haematol       Date:  1981       Impact factor: 2.195

Review 6.  Chronic idiopathic thrombocytopenic purpura.

Authors:  R McMillan
Journal:  N Engl J Med       Date:  1981-05-07       Impact factor: 91.245

7.  Further characterization of the human inducer T cell subset defined by monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

8.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

9.  Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.

Authors:  J Römer; J J Morgenthaler; R Scherz; F Skvaril
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

10.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.

Authors:  E L Reinherz; P C Kung; G Goldstein; R H Levey; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

  10 in total
  25 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

4.  Cellular changes during the infusion of high dose intravenous immunoglobulin.

Authors:  A C Newland; M G Macey; P A Veys
Journal:  Blut       Date:  1989-07

5.  Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin.

Authors:  N Kondo; T Ozawa; K Mushiake; F Motoyoshi; T Kameyama; K Kasahara; H Kaneko; M Yamashina; Y Kato; T Orii
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

6.  Stimulation of the respiratory burst and promotion of bacterial killing in human granulocytes by intravenous immunoglobulin preparations.

Authors:  L Maródi; A Kalmár; L Karmazsin
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

7.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 8.  Intravenous immune globulin in recurrent abortion.

Authors:  O Heine; G Mueller-Eckhardt
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  In vitro synthesis of human IgE is suppressed by human IgG.

Authors:  H Haas; M Schlaak
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.